Leadership Team

Kimberly Kelly, PhD founded and has led ZielBio for 5 years. Dr. Kelly is a biomedical engineer specializing in therapeutic target identification. She trained at Hamilton College in Chemistry before receiving her PhD at the Huntsman Cancer Institute at the University of Utah. Dr. Kelly did a postdoctoral fellowship at Massachusetts General Hospital before becoming a Full Professor of Biomedical Engineering at the University of Virginia.  Dr. Kelly serves as reviewer and is on the editorial board of numerous scientific journals, including Molecular Imaging and Biology, Cancer Research, and as the President of the Center for Molecular Imaging Innovation and Translation in SNMMI. A frequent lecturer, she has published over 65 scientific manuscripts and is the inventor of over 20 granted patents and patent applications.

Dieter Weinand is an experienced executive with over 30 years of experience in the pharmaceuticals and biotech industries. Mr. Weinand presently serves as the Chairman of the Board of Directors of Replimune Group Inc. (NASDAQ: REPL). Previously, Mr. Weinand served as the Executive Vice President of Primary Care and was a member of the Executive Committee at Sanofi from November 2018 to March 2020. Before moving to Sanofi, he was CEO and Chairman of the Board of Management of Bayer Pharma AG and member of the Management Board at Bayer AG. Prior to his work at Sanofi and Bayer, Mr. Weinand held various positions in commercial, operational, and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb, and Otsuka. Mr. Weinand is a former board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the European Federation of Pharmaceutical Industries & Associations (EFPIA), and the International Federation of Pharmaceutical Manufacturers (IFPMA), and served as a member of the Board of Directors of HealthPrize Technologies.

Brian Schwartz, MD, has deep experience as a drug development expert in the pharmaceutical and biotechnology industries. Dr. Schwartz most recently served as Chief Medical Officer and head of Research and Development of ArQule, Inc. where he served as a key member of the management team and spearheaded a number of preclinical and clinical drug development programs in oncology and rare diseases. Prior to joining ArQule in 2008, Dr. Schwartz served as Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm Oncology, Inc., where he built and led clinical, regulatory, and quality assurance departments responsible for the development of new cancer drugs. Earlier in his career, Dr. Schwartz held positions of increasing responsibility at Bayer Healthcare and Leo Laboratories. Dr. Schwartz received his medical degree from the University of Pretoria, South Africa, practiced medicine, and worked at the University of Toronto prior to his career in the biopharmaceutical industry. Dr Schwartz currently serves as an advisor to the California Institute of Regenerative Medicine and as a board member of several biotech companies.

Gregg Beloff has more than 20 years of experience in the life science industry, ranging from venture-backed start-ups to publicly traded companies. Gregg is the co-founder and managing director of Danforth Advisors, a company focused on providing finance support and strategy for life science companies. He previously served as CFO of four public and over 20 privately held companies, during which time he managed finance, accounting, corporate communications, human resources, IT, facilities, legal, IP, business development and manufacturing functions. Gregg’s core expertise includes operational management, strategic planning and corporate and business development, fundraising and mergers and acquisitions. Prior to his CFO roles, Gregg was a life science investment banker with Adams, Harkness & Hill, where he underwrote financings for and provided buy- and sell-side M&A counsel to biotechnology, medical device, and healthcare information technology companies. He began his career as a corporate attorney with Gaffin & Krattenmaker, a Boston-based law firm. He received a BA from Middlebury College, a JD from the University of Pittsburgh School of Law and an MBA from Carnegie Mellon University.